Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Incyte Corporation clinical trials
The registry lists 314 studies whose lead sponsor is Incyte Corporation or one of 6 companies grouped under it. 38 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 22, 2026.
Keep track of what changes. Save the Incyte Corporation studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Incyte Corporation.
- Incyte Corporation288 studiesSame company
Something wrong?
- Incyte Biosciences International Sàrl10 studies →Acquired — became part of Incyte Corporation, Jun 1, 2016 · source ↗
Something wrong?
- Incyte Biosciences Japan GK6 studies →Regional office
Something wrong?
- Escient Pharmaceuticals, Inc6 studies →Acquired — became part of Incyte Corporation, May 30, 2024 · source ↗
Something wrong?
- Vega Therapeutics, Inc2 studies →Acquired — became part of Incyte Corporation, Jul 6, 2026 · source ↗
Something wrong?
- Incyte Biosciences UK1 study →Acquired — became part of Incyte Corporation, Jun 1, 2016 · source ↗
Something wrong?
- Incyte BioSciences France1 study →Acquired — became part of Incyte Corporation, Jun 1, 2016 · source ↗
Something wrong?
Focus areas
Conditions Incyte Corporation leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Myeloproliferative Disorders23Neoplasms22Primary Myelofibrosis22Carcinoma, Non-Small-Cell Lung20Dermatitis, Atopic17Lymphoma17Eczema16Colorectal Neoplasms15Lymphoma, Large B-Cell, Diffuse13Bronchiolitis Obliterans Syndrome12Carcinoma, Renal Cell12Dermatitis12Hidradenitis Suppurativa12Lung Neoplasms12Neoplasm Metastasis12Ovarian Neoplasms12Melanoma11Thrombocythemia, Essential11Graft vs Host Disease10Polycythemia Vera10Squamous Cell Carcinoma of Head and Neck10
Studies
Recruiting first, then most recently updated. Showing 50 of 314. Browse all 314 →
- To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans ProgressivaRecruitingNCT05090891Phase 2
- A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)RecruitingNCT06615050Phase 3
- A Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma With FGFR2 Fusion or Rearrangements After at Least 1 Prior Line of Systemic TherapyNot yet recruitingNCT07862998Phase 2
- A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential ThrombocythemiaRecruitingNCT07623200Phase 3
- Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 OverexpressionRecruitingNCT07214779Phase 3
- Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid TumorsRecruitingNCT03934372Phase 1/2
Sponsor listed in the registry: Incyte Biosciences International Sàrl · First submitted after Incyte Biosciences International Sàrl became part of Incyte Corporation
- A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host DiseaseRecruitingNCT06585774Phase 3
- A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental VitiligoRecruitingNCT06804811Phase 3
- Rollover Study for Participants Previously Enrolled in Clinical Trials of PovorcitinibRecruitingNCT06855498Phase 3
- A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)RecruitingNCT07124078Phase 2
- A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological MalignanciesRecruitingNCT07195916Phase 1
- Study of INCA036978 in Participants With Myeloproliferative NeoplasmsRecruitingNCT07441694Phase 1
- Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis SuppurativaRecruitingNCT07213973Phase 2
- Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis SuppurativaRecruitingNCT07049575Phase 1
- A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal CancerRecruitingNCT07284849Phase 3
- A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal AdenocarcinomaRecruitingNCT07522073Phase 3
- Observational Study for Patients at Risk for Chronic Graft-Versus-Host DiseaseRecruitingNCT05919511
- Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1Not yet recruitingNCT07797283Phase 3
- A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Impaired Renal Function and Participants on HemodialysisNot yet recruitingNCT07854249Phase 1
- A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Hepatic ImpairmentNot yet recruitingNCT07853040Phase 1
- A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection and ChemotherapyNot yet recruitingNCT07823322Phase 2
- A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 OverexpressionRecruitingNCT07023627Phase 2
- Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)RecruitingNCT07115004Phase 3
Sponsor listed in the registry: Vega Therapeutics, Inc · First submitted before Vega Therapeutics, Inc became part of Incyte Corporation
- A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental VitiligoRecruitingNCT06548360Phase 3
- Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell DisordersRecruitingNCT07104565Phase 2
- A Study to Evaluate INCA035784 in Participants With Myeloproliferative NeoplasmsRecruitingNCT07008118Phase 1
- A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT05836324Phase 1
- A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D MutationRecruitingNCT06179160Phase 1
- A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult ParticipantsRecruitingNCT07448155Phase 1
- A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal DiseaseRecruitingNCT07559396Phase 1
- A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic ImpairmentRecruitingNCT07559474Phase 1
- Expanded Access Use of Itacitinib to Treat a Single Patient With STAT1 Gain of Function (GOF) DiseaseAvailableNCT05561985
- A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmsRecruitingNCT06034002Phase 1
- An Early Access Program Guideline to Provide Access to Retifanlimab (INCMGA00012) Together With Carboplatin and Paclitaxel for Squamous Carcinoma of the Anal Canal (SCAC)AvailableNCT06910137
- An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database AnalysisRecruitingNCT06627335
- Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control PopulationRecruitingNCT06259669
- Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With TafasitamabRecruitingNCT06465433Phase 2
- Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)RecruitingNCT05776069Phase 1/2
Sponsor listed in the registry: Vega Therapeutics, Inc · First submitted before Vega Therapeutics, Inc became part of Incyte Corporation
- Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)Active, not recruitingNCT05429268Phase 3
- To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)Active, not recruitingNCT04661007Phase 1/2
Sponsor listed in the registry: Incyte Biosciences Japan GK
- A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell CarcinomaTerminatedNCT05888844Phase 2
- A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor NaiveTerminatedNCT05879822Phase 2
- A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic DermatitisCompletedNCT06238817Phase 3
- A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host DiseaseActive, not recruitingNCT06388564Phase 2
- A Study to Assess the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB161734 in Healthy Male ParticipantsActive, not recruitingNCT07814404Phase 1
- A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult ParticipantsCompletedNCT07588139Phase 1
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host DiseaseActive, not recruitingNCT06263478Phase 3
Sponsor listed in the registry: Incyte Biosciences Japan GK
- INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative DisordersCompletedNCT04455841Phase 1/2
- Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)CompletedNCT03358472Phase 3
- Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedNCT05287113Phase 2
Sponsor listed in the registry: Incyte Biosciences International Sàrl · First submitted after Incyte Biosciences International Sàrl became part of Incyte Corporation